[go: up one dir, main page]

EE200300408A - Aktiivsete valkude saagise suurendamine - Google Patents

Aktiivsete valkude saagise suurendamine

Info

Publication number
EE200300408A
EE200300408A EEP200300408A EEP200300408A EE200300408A EE 200300408 A EE200300408 A EE 200300408A EE P200300408 A EEP200300408 A EE P200300408A EE P200300408 A EEP200300408 A EE P200300408A EE 200300408 A EE200300408 A EE 200300408A
Authority
EE
Estonia
Prior art keywords
increasing
yield
active proteins
proteins
preparations
Prior art date
Application number
EEP200300408A
Other languages
English (en)
Inventor
M. Sassenfeld Helmut
L. Remmele Richard Jr.
E. Mccoy Rebecca
Original Assignee
Immunex Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23033913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200300408(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corporation filed Critical Immunex Corporation
Publication of EE200300408A publication Critical patent/EE200300408A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Automatic Analysis And Handling Materials Therefor (AREA)
  • Measurement Of Radiation (AREA)
EEP200300408A 2001-02-23 2002-02-22 Aktiivsete valkude saagise suurendamine EE200300408A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27103301P 2001-02-23 2001-02-23
PCT/US2002/005645 WO2002068455A2 (en) 2001-02-23 2002-02-22 Efficient recovery of correctly refolded proteins

Publications (1)

Publication Number Publication Date
EE200300408A true EE200300408A (et) 2003-12-15

Family

ID=23033913

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300408A EE200300408A (et) 2001-02-23 2002-02-22 Aktiivsete valkude saagise suurendamine

Country Status (20)

Country Link
US (2) US7157557B2 (et)
EP (1) EP1366062B1 (et)
JP (1) JP2005505494A (et)
KR (1) KR20040052481A (et)
CN (1) CN1547586A (et)
AT (1) ATE517909T1 (et)
AU (1) AU2002255600B2 (et)
BG (1) BG108087A (et)
CA (1) CA2438094C (et)
CZ (1) CZ20032208A3 (et)
EE (1) EE200300408A (et)
ES (1) ES2370235T3 (et)
HU (1) HUP0303246A2 (et)
IL (1) IL157446A0 (et)
MX (1) MXPA03007563A (et)
PL (1) PL374045A1 (et)
RU (1) RU2316563C2 (et)
SK (1) SK10472003A3 (et)
WO (1) WO2002068455A2 (et)
ZA (1) ZA200305909B (et)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200300408A (et) * 2001-02-23 2003-12-15 Immunex Corporation Aktiivsete valkude saagise suurendamine
CA2536918A1 (en) 2003-08-26 2005-03-03 Leland Shapiro Compositions of, and methods for, alpha-1 antitrypsin fc fusion molecules
EP1805205A1 (en) * 2004-10-22 2007-07-11 Amgen Inc. Methods for refolding polypeptides
JP5553963B2 (ja) * 2004-10-22 2014-07-23 アムジエン・インコーポレーテツド 組換え抗体をリフォールディングする方法
WO2006079176A1 (en) * 2005-01-28 2006-08-03 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
MX2007014148A (es) 2005-05-19 2008-01-11 Amgen Inc Composiciones y metodos para incrementar la estabilidad de anticuerpos.
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc SELF-BUFFING PROTEIN FORMULATIONS
EP1893632B1 (en) * 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
AU2006343279B2 (en) 2005-12-22 2012-03-29 Genentech, Inc. Recombinant production of heparin binding proteins
US9012605B2 (en) 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
ZA200900229B (en) 2006-07-14 2010-04-28 Genentech Inc Refolding of recombinant proteins
WO2008051363A2 (en) 2006-10-20 2008-05-02 Amgen Inc. Stable polypeptide formulations
KR102055873B1 (ko) 2007-07-09 2019-12-13 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
ES3006441T3 (en) * 2007-09-14 2025-03-18 Amgen Inc Homogeneous antibody populations
MX2011013898A (es) 2009-06-22 2012-05-22 Amgen Inc Proteínas replegadas que usan un estado de oxido-reduccion quimicamente controlado.
FI3660032T3 (fi) 2009-06-25 2025-12-18 Amgen Inc Ei-nisäkäsperäisessä järjestelmässä ekspressoitujen proteiinien sieppauspuhdistusmenetelmiä
US9005926B2 (en) 2009-10-02 2015-04-14 Biogen Idec Ma Inc. Methods of preventing and removing trisulfide bonds
WO2011068993A1 (en) * 2009-12-02 2011-06-09 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life of fc fusion proteins.
WO2012109162A1 (en) 2011-02-07 2012-08-16 Cerenis Therapeutics Holding S.A. Lipoprotein complexes and manufacturing and uses thereof
EP2718328A4 (en) 2011-06-08 2014-12-24 Acceleron Pharma Inc COMPOSITIONS AND METHODS FOR INCREASING THE HALF TIME OF SERUM
EP2723370A4 (en) 2011-06-24 2015-06-03 Univ Colorado Regents COMPOSITIONS, PROCESS AND USE OF ALPHA-1-ANTITRYPHIN FUSION MOLECULES
US10478508B2 (en) 2012-01-10 2019-11-19 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
US9353165B2 (en) * 2012-07-25 2016-05-31 Grifols, S.A. Purification of cell culture derived alpha1 protease inhibitor
ES2633894T3 (es) 2012-08-02 2017-09-25 F. Hoffmann-La Roche Ag Procedimiento para producir moléculas monoméricas y multiméricas y usos de las mismas
BR112015005161A2 (pt) 2012-09-11 2017-07-04 Coherus Biosciences Inc etanercepte corretamente dobrado em alta pureza e excelente rendimento
RU2768003C2 (ru) 2013-03-08 2022-03-22 Джензим Корпорейшн Интегрированное непрерывное производство терапевтических белковых лекарственных веществ
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
TWI709570B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析法及製法
AR103172A1 (es) 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
KR102446838B1 (ko) 2016-10-21 2022-09-26 암젠 인크 약학적 제형 및 그의 제조 방법
KR102824467B1 (ko) 2018-08-31 2025-06-26 젠자임 코포레이션 멸균 크로마토그래피 수지 및 제조 공정에서 이의 용도
CN112789058A (zh) 2018-10-11 2021-05-11 安进公司 双特异性抗体构建体的下游加工
US12516103B2 (en) 2020-12-22 2026-01-06 Amgen Inc. Cell culture method
WO2025128536A1 (en) * 2023-12-14 2025-06-19 Genentech, Inc. Disulfide isoform modulation
CN118047854B (zh) * 2024-02-26 2024-08-02 武汉鹰达生物科技有限公司 一种人载脂蛋白a-i的分离纯化方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453363A (en) * 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
US4766205A (en) * 1985-11-13 1988-08-23 Beatrice Companies, Inc. Method for isolation of recombinant polypeptides in biologically active forms
AU626524B2 (en) * 1987-05-29 1992-08-06 Bristol-Myers Squibb Company Cloning and expression of simian transforming growth factor- beta 1
US4970067A (en) * 1988-12-12 1990-11-13 Helene Curtis, Inc. Method and composition to condition hair and impart semi-permanent hair set retention properties
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
AU648214B2 (en) * 1991-12-31 1994-04-14 Lucky Limited Recombinant gene coding for human alpha interferon and expression vector thereof, etc.
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
NZ271088A (en) * 1993-08-04 1996-10-28 Ciba Geigy Ag Desulphatohirudin muteins, their production, conjugates thereof and pharmaceutical compositions
CA2139385C (en) * 1994-02-04 2001-12-25 Gottfried Alber Products containing g-csf and tnf binding protein
US6310185B1 (en) * 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
AU2603995A (en) * 1994-05-25 1995-12-18 University Of Nebraska Board Of Regents Biologically active glycoprotein hormones produced in procaryotic cells
FI970247L (fi) 1994-07-22 1997-01-21 Hoffmann La Roche Farmaseuttisia koostumuksia, jotka sisältävät kimeerisen TNF:ää sitovan proteiinin
US5879673A (en) * 1996-01-25 1999-03-09 Genentech, Inc. Administration of thrombopoietin on a single day only
US5935824A (en) * 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
FR2803303B1 (fr) * 2000-01-04 2002-05-10 Aventis Pasteur Glycoproteine d'enveloppe du vih modifiee chimiquement
EE200300408A (et) * 2001-02-23 2003-12-15 Immunex Corporation Aktiivsete valkude saagise suurendamine

Also Published As

Publication number Publication date
SK10472003A3 (sk) 2004-03-02
KR20040052481A (ko) 2004-06-23
US7544784B2 (en) 2009-06-09
EP1366062A2 (en) 2003-12-03
EP1366062B1 (en) 2011-07-27
RU2003127830A (ru) 2005-04-10
CA2438094C (en) 2011-10-11
JP2005505494A (ja) 2005-02-24
PL374045A1 (en) 2005-09-19
US20070270577A1 (en) 2007-11-22
AU2002255600B2 (en) 2008-01-24
RU2316563C2 (ru) 2008-02-10
HK1059267A1 (en) 2004-06-25
MXPA03007563A (es) 2003-12-11
ES2370235T3 (es) 2011-12-13
WO2002068455A3 (en) 2003-09-18
US20020182665A1 (en) 2002-12-05
ATE517909T1 (de) 2011-08-15
CZ20032208A3 (cs) 2004-01-14
BG108087A (bg) 2005-04-30
CA2438094A1 (en) 2002-09-06
HUP0303246A2 (hu) 2003-12-29
US7157557B2 (en) 2007-01-02
ZA200305909B (en) 2004-06-04
WO2002068455A2 (en) 2002-09-06
IL157446A0 (en) 2004-03-28
CN1547586A (zh) 2004-11-17

Similar Documents

Publication Publication Date Title
EE200300408A (et) Aktiivsete valkude saagise suurendamine
NO2020016I1 (no) efmoroktokog alfa - forlenget SPC
EA200700917A1 (ru) Способ рефолдинга рекомбинантных антител
DE602004011770D1 (de) Fusionsproteine
ATE380822T1 (de) Funf-helix protein
EP2298331A3 (en) Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
ATE408631T1 (de) Chimäres protein welches eine intramolekulare chaperon-ähnliche sequenz enthält und dessen anwendung zur insulinproduktion
DK1368372T3 (da) Peptid med affinitet til det virale gp120-protein samt anvendelse deraf
DK1412503T3 (da) Et fusionsprotein
EA200500624A1 (ru) Промотор для il-18bp, его получение и применение
ATE325873T1 (de) Androgenrezeptor-komplex assoziiertes protein
AU2003280359A1 (en) Phosphoamidase assay
AU2013245463B2 (en) Immunoglobulin Chimeric Monomer-Dimer Hybrids
WO2003048320A3 (en) Novel motor protein of p. falciparum and methods for its use